organization · Reporting owner
Perceptive LS (A), LLC
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Lyra Therapeutics, Inc.
Report date November 11, 2025 · Filed November 13, 2025
Jointly reported with PERCEPTIVE ADVISORS LLC, PERCEPTIVE LIFE SCIENCES MASTER FUND LTD, EDELMAN JOSEPH
Section 16 reporting ended · disclosed 2025-11-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 161,318 |
Reported balance
After 2025-11-11 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2025-11-11 · Sale · Disposed 4,783 · Balance 161,318 F1: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.25 to $4.61 inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within such range. F2: Perceptive Advisors, LLC (the "Advisor") serves as the investment advisor to Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund"). Perceptive LS GP, LLC ("GP") is the manager of Perceptive LS (A), LLC ("Perceptive LS"). Joseph Edelman is the managing member of the Advisor and the sole member of GP. Each of Mr. Edelman, GP and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that Mr. Edelman, GP or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. F3: The securities reported in this row are held by the Master Fund. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 18,122 |
Reported balance
After 2025-11-11 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2025-11-11 · Sale · Disposed 537 · Balance 18,122 F1: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.25 to $4.61 inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within such range. F2: Perceptive Advisors, LLC (the "Advisor") serves as the investment advisor to Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund"). Perceptive LS GP, LLC ("GP") is the manager of Perceptive LS (A), LLC ("Perceptive LS"). Joseph Edelman is the managing member of the Advisor and the sole member of GP. Each of Mr. Edelman, GP and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that Mr. Edelman, GP or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. F4: The securities reported in this row are held by Perceptive LS. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 153,456 |
Reported balance
After 2025-11-12 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2025-11-12 · Sale · Disposed 7,862 · Balance 153,456 F5: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.90 to $4.27 inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within such range. F2: Perceptive Advisors, LLC (the "Advisor") serves as the investment advisor to Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund"). Perceptive LS GP, LLC ("GP") is the manager of Perceptive LS (A), LLC ("Perceptive LS"). Joseph Edelman is the managing member of the Advisor and the sole member of GP. Each of Mr. Edelman, GP and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that Mr. Edelman, GP or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. F3: The securities reported in this row are held by the Master Fund. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 17,239 |
Reported balance
After 2025-11-12 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2025-11-12 · Sale · Disposed 883 · Balance 17,239 F5: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.90 to $4.27 inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within such range. F2: Perceptive Advisors, LLC (the "Advisor") serves as the investment advisor to Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund"). Perceptive LS GP, LLC ("GP") is the manager of Perceptive LS (A), LLC ("Perceptive LS"). Joseph Edelman is the managing member of the Advisor and the sole member of GP. Each of Mr. Edelman, GP and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that Mr. Edelman, GP or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. F4: The securities reported in this row are held by Perceptive LS. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 124,859 |
Reported balance
After 2025-11-13 transaction · row 5
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 5 · 2025-11-13 · Sale · Disposed 28,597 · Balance 124,859 F6: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.90 to $3.91 inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within such range. F2: Perceptive Advisors, LLC (the "Advisor") serves as the investment advisor to Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund"). Perceptive LS GP, LLC ("GP") is the manager of Perceptive LS (A), LLC ("Perceptive LS"). Joseph Edelman is the managing member of the Advisor and the sole member of GP. Each of Mr. Edelman, GP and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that Mr. Edelman, GP or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. F3: The securities reported in this row are held by the Master Fund. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 14,026 |
Reported balance
After 2025-11-13 transaction · row 6
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 6 · 2025-11-13 · Sale · Disposed 3,213 · Balance 14,026 F6: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.90 to $3.91 inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within such range. F2: Perceptive Advisors, LLC (the "Advisor") serves as the investment advisor to Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund"). Perceptive LS GP, LLC ("GP") is the manager of Perceptive LS (A), LLC ("Perceptive LS"). Joseph Edelman is the managing member of the Advisor and the sole member of GP. Each of Mr. Edelman, GP and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that Mr. Edelman, GP or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. F4: The securities reported in this row are held by Perceptive LS. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.25 to $4.61 inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within such range.
F2: Perceptive Advisors, LLC (the "Advisor") serves as the investment advisor to Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund"). Perceptive LS GP, LLC ("GP") is the manager of Perceptive LS (A), LLC ("Perceptive LS"). Joseph Edelman is the managing member of the Advisor and the sole member of GP. Each of Mr. Edelman, GP and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that Mr. Edelman, GP or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.
F3: The securities reported in this row are held by the Master Fund.
F4: The securities reported in this row are held by Perceptive LS.
F5: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.90 to $4.27 inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within such range.
F6: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.90 to $3.91 inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within such range.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 13, 2025 Filed Nov 13, 2025 22:07 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | SaleCommon Stock | 3,213 | $3.90 | $12,531.02 |
DisclosureSEC source: 0001193125-25-280481 · ownership.xml · nonDerivative · entry 6 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · 10% owner Perceptive LS (A), LLC · CIK 0001797811 · 10% owner EDELMAN JOSEPH · CIK 0001164426 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 14,026 F6 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.90 to $3.91 inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within such range. F2 · ownership.nature: Perceptive Advisors, LLC (the "Advisor") serves as the investment advisor to Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund"). Perceptive LS GP, LLC ("GP") is the manager of Perceptive LS (A), LLC ("Perceptive LS"). Joseph Edelman is the managing member of the Advisor and the sole member of GP. Each of Mr. Edelman, GP and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that Mr. Edelman, GP or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. F4 · ownership.nature: The securities reported in this row are held by Perceptive LS. Read SEC document |
| November 13, 2025 Filed Nov 13, 2025 22:07 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | SaleCommon Stock | 28,597 | $3.90 | $111,531.16 |
DisclosureSEC source: 0001193125-25-280481 · ownership.xml · nonDerivative · entry 5 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · 10% owner Perceptive LS (A), LLC · CIK 0001797811 · 10% owner EDELMAN JOSEPH · CIK 0001164426 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 124,859 F6 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.90 to $3.91 inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within such range. F2 · ownership.nature: Perceptive Advisors, LLC (the "Advisor") serves as the investment advisor to Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund"). Perceptive LS GP, LLC ("GP") is the manager of Perceptive LS (A), LLC ("Perceptive LS"). Joseph Edelman is the managing member of the Advisor and the sole member of GP. Each of Mr. Edelman, GP and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that Mr. Edelman, GP or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. F3 · ownership.nature: The securities reported in this row are held by the Master Fund. Read SEC document |
| November 12, 2025 Filed Nov 13, 2025 22:07 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | SaleCommon Stock | 883 | $4.06 | $3,584.45 |
DisclosureSEC source: 0001193125-25-280481 · ownership.xml · nonDerivative · entry 4 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · 10% owner Perceptive LS (A), LLC · CIK 0001797811 · 10% owner EDELMAN JOSEPH · CIK 0001164426 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 17,239 F5 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.90 to $4.27 inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within such range. F2 · ownership.nature: Perceptive Advisors, LLC (the "Advisor") serves as the investment advisor to Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund"). Perceptive LS GP, LLC ("GP") is the manager of Perceptive LS (A), LLC ("Perceptive LS"). Joseph Edelman is the managing member of the Advisor and the sole member of GP. Each of Mr. Edelman, GP and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that Mr. Edelman, GP or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. F4 · ownership.nature: The securities reported in this row are held by Perceptive LS. Read SEC document |
| November 12, 2025 Filed Nov 13, 2025 22:07 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | SaleCommon Stock | 7,862 | $4.06 | $31,915.00 |
DisclosureSEC source: 0001193125-25-280481 · ownership.xml · nonDerivative · entry 3 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · 10% owner Perceptive LS (A), LLC · CIK 0001797811 · 10% owner EDELMAN JOSEPH · CIK 0001164426 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 153,456 F5 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.90 to $4.27 inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within such range. F2 · ownership.nature: Perceptive Advisors, LLC (the "Advisor") serves as the investment advisor to Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund"). Perceptive LS GP, LLC ("GP") is the manager of Perceptive LS (A), LLC ("Perceptive LS"). Joseph Edelman is the managing member of the Advisor and the sole member of GP. Each of Mr. Edelman, GP and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that Mr. Edelman, GP or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. F3 · ownership.nature: The securities reported in this row are held by the Master Fund. Read SEC document |
| November 11, 2025 Filed Nov 13, 2025 22:07 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | SaleCommon Stock | 537 | $4.31 | $2,316.94 |
DisclosureSEC source: 0001193125-25-280481 · ownership.xml · nonDerivative · entry 2 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · 10% owner Perceptive LS (A), LLC · CIK 0001797811 · 10% owner EDELMAN JOSEPH · CIK 0001164426 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 18,122 F1 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.25 to $4.61 inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within such range. F2 · ownership.nature: Perceptive Advisors, LLC (the "Advisor") serves as the investment advisor to Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund"). Perceptive LS GP, LLC ("GP") is the manager of Perceptive LS (A), LLC ("Perceptive LS"). Joseph Edelman is the managing member of the Advisor and the sole member of GP. Each of Mr. Edelman, GP and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that Mr. Edelman, GP or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. F4 · ownership.nature: The securities reported in this row are held by Perceptive LS. Read SEC document |
| November 11, 2025 Filed Nov 13, 2025 22:07 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | SaleCommon Stock | 4,783 | $4.31 | $20,636.73 |
DisclosureSEC source: 0001193125-25-280481 · ownership.xml · nonDerivative · entry 1 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · 10% owner Perceptive LS (A), LLC · CIK 0001797811 · 10% owner EDELMAN JOSEPH · CIK 0001164426 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 161,318 F1 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.25 to $4.61 inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within such range. F2 · ownership.nature: Perceptive Advisors, LLC (the "Advisor") serves as the investment advisor to Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund"). Perceptive LS GP, LLC ("GP") is the manager of Perceptive LS (A), LLC ("Perceptive LS"). Joseph Edelman is the managing member of the Advisor and the sole member of GP. Each of Mr. Edelman, GP and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that Mr. Edelman, GP or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. F3 · ownership.nature: The securities reported in this row are held by the Master Fund. Read SEC document |
| November 10, 2025 Filed Nov 10, 2025 22:08 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | SaleCommon Stock | 1,869 | $4.54 | $8,484.89 |
DisclosureSEC source: 0001193125-25-274540 · ownership.xml · nonDerivative · entry 6 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · 10% owner Perceptive LS (A), LLC · CIK 0001797811 · 10% owner EDELMAN JOSEPH · CIK 0001164426 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 18,659 F6 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.5 to $4.675 inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within such range. F2 · ownership.nature: Perceptive Advisors, LLC (the "Advisor") serves as the investment advisor to Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund"). Perceptive LS GP, LLC ("GP") is the manager of Perceptive LS (A), LLC ("Perceptive LS"). Joseph Edelman is the managing member of the Advisor and the sole member of GP. Each of Mr. Edelman, GP and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that Mr. Edelman, GP or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. F4 · ownership.nature: The securities reported in this row are held by Perceptive LS. Read SEC document |
| November 10, 2025 Filed Nov 10, 2025 22:08 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | SaleCommon Stock | 16,633 | $4.54 | $75,510.49 |
DisclosureSEC source: 0001193125-25-274540 · ownership.xml · nonDerivative · entry 5 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · 10% owner Perceptive LS (A), LLC · CIK 0001797811 · 10% owner EDELMAN JOSEPH · CIK 0001164426 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 166,101 F6 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.5 to $4.675 inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within such range. F2 · ownership.nature: Perceptive Advisors, LLC (the "Advisor") serves as the investment advisor to Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund"). Perceptive LS GP, LLC ("GP") is the manager of Perceptive LS (A), LLC ("Perceptive LS"). Joseph Edelman is the managing member of the Advisor and the sole member of GP. Each of Mr. Edelman, GP and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that Mr. Edelman, GP or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. F3 · ownership.nature: The securities reported in this row are held by the Master Fund. Read SEC document |
| November 07, 2025 Filed Nov 10, 2025 22:08 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | SaleCommon Stock | 1,993 | $4.75 | $9,460.17 |
DisclosureSEC source: 0001193125-25-274540 · ownership.xml · nonDerivative · entry 4 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · 10% owner Perceptive LS (A), LLC · CIK 0001797811 · 10% owner EDELMAN JOSEPH · CIK 0001164426 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 20,528 F5 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.61 to $4.9 inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within such range. F2 · ownership.nature: Perceptive Advisors, LLC (the "Advisor") serves as the investment advisor to Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund"). Perceptive LS GP, LLC ("GP") is the manager of Perceptive LS (A), LLC ("Perceptive LS"). Joseph Edelman is the managing member of the Advisor and the sole member of GP. Each of Mr. Edelman, GP and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that Mr. Edelman, GP or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. F4 · ownership.nature: The securities reported in this row are held by Perceptive LS. Read SEC document |
| November 07, 2025 Filed Nov 10, 2025 22:08 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | SaleCommon Stock | 17,746 | $4.75 | $84,234.94 |
DisclosureSEC source: 0001193125-25-274540 · ownership.xml · nonDerivative · entry 3 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · 10% owner Perceptive LS (A), LLC · CIK 0001797811 · 10% owner EDELMAN JOSEPH · CIK 0001164426 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 182,734 F5 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.61 to $4.9 inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within such range. F2 · ownership.nature: Perceptive Advisors, LLC (the "Advisor") serves as the investment advisor to Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund"). Perceptive LS GP, LLC ("GP") is the manager of Perceptive LS (A), LLC ("Perceptive LS"). Joseph Edelman is the managing member of the Advisor and the sole member of GP. Each of Mr. Edelman, GP and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that Mr. Edelman, GP or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. F3 · ownership.nature: The securities reported in this row are held by the Master Fund. Read SEC document |
| November 06, 2025 Filed Nov 10, 2025 22:08 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | SaleCommon Stock | 3,247 | $5.18 | $16,819.14 |
DisclosureSEC source: 0001193125-25-274540 · ownership.xml · nonDerivative · entry 2 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · 10% owner Perceptive LS (A), LLC · CIK 0001797811 · 10% owner EDELMAN JOSEPH · CIK 0001164426 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 22,521 F1 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.85 to $5.65 inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within such range. F2 · ownership.nature: Perceptive Advisors, LLC (the "Advisor") serves as the investment advisor to Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund"). Perceptive LS GP, LLC ("GP") is the manager of Perceptive LS (A), LLC ("Perceptive LS"). Joseph Edelman is the managing member of the Advisor and the sole member of GP. Each of Mr. Edelman, GP and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that Mr. Edelman, GP or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. F4 · ownership.nature: The securities reported in this row are held by Perceptive LS. Read SEC document |
| November 06, 2025 Filed Nov 10, 2025 22:08 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | SaleCommon Stock | 28,902 | $5.18 | $149,709.47 |
DisclosureSEC source: 0001193125-25-274540 · ownership.xml · nonDerivative · entry 1 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · 10% owner Perceptive LS (A), LLC · CIK 0001797811 · 10% owner EDELMAN JOSEPH · CIK 0001164426 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 200,480 F1 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.85 to $5.65 inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within such range. F2 · ownership.nature: Perceptive Advisors, LLC (the "Advisor") serves as the investment advisor to Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund"). Perceptive LS GP, LLC ("GP") is the manager of Perceptive LS (A), LLC ("Perceptive LS"). Joseph Edelman is the managing member of the Advisor and the sole member of GP. Each of Mr. Edelman, GP and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that Mr. Edelman, GP or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. F3 · ownership.nature: The securities reported in this row are held by the Master Fund. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 20:11 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | PurchaseCommon Stock Purchase Warrant · Derivative | 1,805,416 | Not disclosed Strike: $2.67 | Not disclosed |
DisclosureSEC source: 0001062993-23-012744 · form4.xml · derivative · entry 3 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · 10% owner Perceptive LS (A), LLC · CIK 0001797811 · 10% owner EDELMAN JOSEPH · CIK 0001164426 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 1,805,416 Underlying: Common Stock · 1,805,416 shares Expires 2028-11-30 F4 · price: These securities were acquired in units, with each unit consisting of one share of Common Stock and one Common Stock Purchase Warrant to purchase one share of Common Stock (the "Warrants"), at a combined purchase price of $2.4925 per unit. Each of the Warrants may not be exercised if the Reporting Persons and their affiliates would beneficially own more than 9.9% of the Issuer's outstanding shares of Common Stock following such exercise. F1 · ownership.nature: The securities reported in this row are held by Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund"). Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 20:11 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | PurchaseCommon Stock | 3,610,832 | $2.49 | $8,999,998.76 |
DisclosureSEC source: 0001062993-23-012744 · form4.xml · nonDerivative · entry 1 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · 10% owner Perceptive LS (A), LLC · CIK 0001797811 · 10% owner EDELMAN JOSEPH · CIK 0001164426 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 11,469,117 F4 · price: These securities were acquired in units, with each unit consisting of one share of Common Stock and one Common Stock Purchase Warrant to purchase one share of Common Stock (the "Warrants"), at a combined purchase price of $2.4925 per unit. Each of the Warrants may not be exercised if the Reporting Persons and their affiliates would beneficially own more than 9.9% of the Issuer's outstanding shares of Common Stock following such exercise. F1 · ownership.nature: The securities reported in this row are held by Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund"). F3 · ownership.nature: Perceptive Advisors, LLC (the "Advisor") serves as the investment advisor to the Master Fund. Perceptive LS GP, LLC ("GP") is the manager of Perceptive LS. Joseph Edelman is the managing member of the Advisor and the sole member of GP. Each of Mr. Edelman, GP and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that Mr. Edelman, GP or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| April 12, 2022 Filed Apr 14, 2022 20:53 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | PurchaseCommon Stock | 5,924,170 | $4.22 | $24,999,997.40 |
DisclosureSEC source: 0001062993-22-010256 · form4.xml · nonDerivative · entry 1 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · 10% owner Perceptive LS (A), LLC · CIK 0001797811 · 10% owner EDELMAN JOSEPH · CIK 0001164426 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 7,858,285 F1 · ownership.nature: The securities reported in this row are held by Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund"). F3 · ownership.nature: Perceptive Advisors, LLC (the "Advisor") serves as the investment advisor to the Master Fund. Perceptive LS GP, LLC ("GP") is the manager of Perceptive LS. Joseph Edelman is the managing member of the Advisor and the sole member of GP. Each of Mr. Edelman, GP and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that Mr. Edelman, GP or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| May 05, 2020 Filed May 7, 2020 01:10 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | OtherCommon Warrants · Derivative | 339,604 | $0.00 Strike: $8.63 | $0.00 |
DisclosureSEC source: 0000899243-20-012198 · doc4.xml · derivative · entry 12 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · 10% owner Perceptive LS (A), LLC · CIK 0001797811 · 10% owner EDELMAN JOSEPH · CIK 0001164426 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 339,604 shares Expires 2030-01-10 F2 · ownership.nature: Perceptive Advisors, LLC (the "Advisor") serves as the investment advisor to the Master Fund. Perceptive LS GP, LLC ("GP") is the manager of Perceptive LS (A), LLC ("Perceptive LS"). Joseph Edelman is the managing member of the Advisor and the sole member of GP. Each of Mr. Edelman, GP and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that Mr. Edelman, GP or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. F3 · ownership.nature: The securities reported in this row are held by Perceptive LS. Read SEC document |
| May 05, 2020 Filed May 7, 2020 01:10 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | OtherCommon Warrants · Derivative | 141,221 | $0.00 Strike: $8.63 | $0.00 |
DisclosureSEC source: 0000899243-20-012198 · doc4.xml · derivative · entry 11 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · 10% owner Perceptive LS (A), LLC · CIK 0001797811 · 10% owner EDELMAN JOSEPH · CIK 0001164426 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 141,221 shares Expires 2030-01-10 F1 · ownership.nature: The securities reported in this row are held by Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund"). F2 · ownership.nature: Perceptive Advisors, LLC (the "Advisor") serves as the investment advisor to the Master Fund. Perceptive LS GP, LLC ("GP") is the manager of Perceptive LS (A), LLC ("Perceptive LS"). Joseph Edelman is the managing member of the Advisor and the sole member of GP. Each of Mr. Edelman, GP and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that Mr. Edelman, GP or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| May 05, 2020 Filed May 7, 2020 01:10 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | ConversionSeries C Convertible Preferred Stock · Derivative | 16,232,511 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-012198 · doc4.xml · derivative · entry 10 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · 10% owner Perceptive LS (A), LLC · CIK 0001797811 · 10% owner EDELMAN JOSEPH · CIK 0001164426 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 470,739 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: The preferred stock was convertible at any time, at the holder's election and had no expiration date. Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. F6 · derivative.exercise_date: The preferred stock was convertible at any time, at the holder's election and had no expiration date. Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. F6 · derivative.expiration_date: The preferred stock was convertible at any time, at the holder's election and had no expiration date. Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. F1 · ownership.nature: The securities reported in this row are held by Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund"). F2 · ownership.nature: Perceptive Advisors, LLC (the "Advisor") serves as the investment advisor to the Master Fund. Perceptive LS GP, LLC ("GP") is the manager of Perceptive LS (A), LLC ("Perceptive LS"). Joseph Edelman is the managing member of the Advisor and the sole member of GP. Each of Mr. Edelman, GP and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that Mr. Edelman, GP or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| May 05, 2020 Filed May 7, 2020 01:10 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | ConversionSeries C Convertible Preferred Stock · Derivative | 39,035,325 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-012198 · doc4.xml · derivative · entry 9 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · 10% owner Perceptive LS (A), LLC · CIK 0001797811 · 10% owner EDELMAN JOSEPH · CIK 0001164426 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 1,132,016 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: The preferred stock was convertible at any time, at the holder's election and had no expiration date. Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. F6 · derivative.exercise_date: The preferred stock was convertible at any time, at the holder's election and had no expiration date. Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. F6 · derivative.expiration_date: The preferred stock was convertible at any time, at the holder's election and had no expiration date. Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. F2 · ownership.nature: Perceptive Advisors, LLC (the "Advisor") serves as the investment advisor to the Master Fund. Perceptive LS GP, LLC ("GP") is the manager of Perceptive LS (A), LLC ("Perceptive LS"). Joseph Edelman is the managing member of the Advisor and the sole member of GP. Each of Mr. Edelman, GP and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that Mr. Edelman, GP or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. F3 · ownership.nature: The securities reported in this row are held by Perceptive LS. Read SEC document |
| May 05, 2020 Filed May 7, 2020 01:10 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | ConversionSeries B Convertible Preferred Stock · Derivative | 26,666,666 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-012198 · doc4.xml · derivative · entry 8 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · 10% owner Perceptive LS (A), LLC · CIK 0001797811 · 10% owner EDELMAN JOSEPH · CIK 0001164426 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 773,327 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: The preferred stock was convertible at any time, at the holder's election and had no expiration date. Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. F6 · derivative.exercise_date: The preferred stock was convertible at any time, at the holder's election and had no expiration date. Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. F6 · derivative.expiration_date: The preferred stock was convertible at any time, at the holder's election and had no expiration date. Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. F1 · ownership.nature: The securities reported in this row are held by Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund"). F2 · ownership.nature: Perceptive Advisors, LLC (the "Advisor") serves as the investment advisor to the Master Fund. Perceptive LS GP, LLC ("GP") is the manager of Perceptive LS (A), LLC ("Perceptive LS"). Joseph Edelman is the managing member of the Advisor and the sole member of GP. Each of Mr. Edelman, GP and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that Mr. Edelman, GP or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| May 05, 2020 Filed May 7, 2020 01:10 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | Tax withholdingCommon Stock | 183,174 | $16.00 | $2,930,784.00 |
DisclosureSEC source: 0000899243-20-012198 · doc4.xml · nonDerivative · entry 7 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · 10% owner Perceptive LS (A), LLC · CIK 0001797811 · 10% owner EDELMAN JOSEPH · CIK 0001164426 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,288,446 F5 · kind: On May 5, 2020, the reporting persons exercised a warrant to purchase 339,604 shares of the Issuer's common stock for $16.00 a share. The reporting person paid the exercise price on a cashless basis, resulting in the Issuer's withholding of 183,174 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining shares. The Issuer also paid $1.48 to the reporting person in lieu of a fractional share. F2 · ownership.nature: Perceptive Advisors, LLC (the "Advisor") serves as the investment advisor to the Master Fund. Perceptive LS GP, LLC ("GP") is the manager of Perceptive LS (A), LLC ("Perceptive LS"). Joseph Edelman is the managing member of the Advisor and the sole member of GP. Each of Mr. Edelman, GP and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that Mr. Edelman, GP or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. F3 · ownership.nature: The securities reported in this row are held by Perceptive LS. Read SEC document |
| May 05, 2020 Filed May 7, 2020 01:10 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | OtherCommon Stock | 339,604 | $8.63 | $2,930,782.52 |
DisclosureSEC source: 0000899243-20-012198 · doc4.xml · nonDerivative · entry 6 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · 10% owner Perceptive LS (A), LLC · CIK 0001797811 · 10% owner EDELMAN JOSEPH · CIK 0001164426 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,471,620 F2 · ownership.nature: Perceptive Advisors, LLC (the "Advisor") serves as the investment advisor to the Master Fund. Perceptive LS GP, LLC ("GP") is the manager of Perceptive LS (A), LLC ("Perceptive LS"). Joseph Edelman is the managing member of the Advisor and the sole member of GP. Each of Mr. Edelman, GP and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that Mr. Edelman, GP or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. F3 · ownership.nature: The securities reported in this row are held by Perceptive LS. Read SEC document |
| May 05, 2020 Filed May 7, 2020 01:10 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | Tax withholdingCommon Stock | 76,172 | $16.00 | $1,218,752.00 |
DisclosureSEC source: 0000899243-20-012198 · doc4.xml · nonDerivative · entry 5 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · 10% owner Perceptive LS (A), LLC · CIK 0001797811 · 10% owner EDELMAN JOSEPH · CIK 0001164426 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,309,115 F4 · kind: On May 5, 2020, the reporting persons exercised a warrant to purchsae 141,221 shares of the Issuer's common stock for $16.00 a share. The reporting person paid the exercise price on a cashless basis, resulting in the Issuer's withholding of 76,172 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining shares. The Issuer also paid $14.77 to the reporting person in lieu of a fractional share. F1 · ownership.nature: The securities reported in this row are held by Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund"). F2 · ownership.nature: Perceptive Advisors, LLC (the "Advisor") serves as the investment advisor to the Master Fund. Perceptive LS GP, LLC ("GP") is the manager of Perceptive LS (A), LLC ("Perceptive LS"). Joseph Edelman is the managing member of the Advisor and the sole member of GP. Each of Mr. Edelman, GP and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that Mr. Edelman, GP or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| May 05, 2020 Filed May 7, 2020 01:10 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | OtherCommon Stock | 141,221 | $8.63 | $1,218,737.23 |
DisclosureSEC source: 0000899243-20-012198 · doc4.xml · nonDerivative · entry 4 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · 10% owner Perceptive LS (A), LLC · CIK 0001797811 · 10% owner EDELMAN JOSEPH · CIK 0001164426 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,385,287 F1 · ownership.nature: The securities reported in this row are held by Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund"). F2 · ownership.nature: Perceptive Advisors, LLC (the "Advisor") serves as the investment advisor to the Master Fund. Perceptive LS GP, LLC ("GP") is the manager of Perceptive LS (A), LLC ("Perceptive LS"). Joseph Edelman is the managing member of the Advisor and the sole member of GP. Each of Mr. Edelman, GP and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that Mr. Edelman, GP or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| May 05, 2020 Filed May 7, 2020 01:10 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | ConversionCommon Stock | 470,739 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-012198 · doc4.xml · nonDerivative · entry 3 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · 10% owner Perceptive LS (A), LLC · CIK 0001797811 · 10% owner EDELMAN JOSEPH · CIK 0001164426 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,244,066 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: The securities reported in this row are held by Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund"). F2 · ownership.nature: Perceptive Advisors, LLC (the "Advisor") serves as the investment advisor to the Master Fund. Perceptive LS GP, LLC ("GP") is the manager of Perceptive LS (A), LLC ("Perceptive LS"). Joseph Edelman is the managing member of the Advisor and the sole member of GP. Each of Mr. Edelman, GP and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that Mr. Edelman, GP or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| May 05, 2020 Filed May 7, 2020 01:10 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | ConversionCommon Stock | 1,132,016 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-012198 · doc4.xml · nonDerivative · entry 2 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · 10% owner Perceptive LS (A), LLC · CIK 0001797811 · 10% owner EDELMAN JOSEPH · CIK 0001164426 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,132,016 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · ownership.nature: Perceptive Advisors, LLC (the "Advisor") serves as the investment advisor to the Master Fund. Perceptive LS GP, LLC ("GP") is the manager of Perceptive LS (A), LLC ("Perceptive LS"). Joseph Edelman is the managing member of the Advisor and the sole member of GP. Each of Mr. Edelman, GP and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that Mr. Edelman, GP or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. F3 · ownership.nature: The securities reported in this row are held by Perceptive LS. Read SEC document |
| May 05, 2020 Filed May 7, 2020 01:10 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | ConversionCommon Stock | 773,327 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-012198 · doc4.xml · nonDerivative · entry 1 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · 10% owner Perceptive LS (A), LLC · CIK 0001797811 · 10% owner EDELMAN JOSEPH · CIK 0001164426 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 773,327 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: The securities reported in this row are held by Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund"). F2 · ownership.nature: Perceptive Advisors, LLC (the "Advisor") serves as the investment advisor to the Master Fund. Perceptive LS GP, LLC ("GP") is the manager of Perceptive LS (A), LLC ("Perceptive LS"). Joseph Edelman is the managing member of the Advisor and the sole member of GP. Each of Mr. Edelman, GP and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that Mr. Edelman, GP or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| May 05, 2020 Filed May 29, 2020 21:34 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | PurchaseCommon Stock | 625,000 | $16.00 | $10,000,000.00 |
DisclosureSEC source: 0000899243-20-014580 · doc4.xml · nonDerivative · entry 1 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · 10% owner Perceptive LS (A), LLC · CIK 0001797811 · 10% owner EDELMAN JOSEPH · CIK 0001164426 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,934,115 F1 · ownership.nature: The securities reported in this row are held by Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund"). F3 · ownership.nature: Perceptive Advisors, LLC (the "Advisor") serves as the investment advisor to the Master Fund. Perceptive LS GP, LLC ("GP") is the manager of Perceptive LS. Joseph Edelman is the managing member of the Advisor and the sole member of GP. Each of Mr. Edelman, GP and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that Mr. Edelman, GP or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.